442 related articles for article (PubMed ID: 18556402)
1. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
5. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
6. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
[TBL] [Abstract][Full Text] [Related]
7. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
[TBL] [Abstract][Full Text] [Related]
8. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
[TBL] [Abstract][Full Text] [Related]
9. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma.
Nakamura N; Hashimoto Y; Kuze T; Tasaki K; Sasaki Y; Sato M; Abe M
Lab Invest; 1999 Aug; 79(8):925-33. PubMed ID: 10462030
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
13. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
14. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
[TBL] [Abstract][Full Text] [Related]
15. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas.
Manazza AD; Bonello L; Pagano M; Chiusa L; Novero D; Stacchini A; Martini G; Vitolo U; Tarella C; Inghirami G; Palestro G; Chiarle R
Am J Clin Pathol; 2005 Aug; 124(2):182-90. PubMed ID: 16040287
[TBL] [Abstract][Full Text] [Related]
16. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
19. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
20. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
